Among the most popular portfolio startups of the fund, we may highlight IGEM Therapeutics. We can highlight the next thriving fund investment areas, such as Genetics, Biotechnology. Besides, a startup needs to be aged 2-3 years to get the investment from the fund.
The typical case for the fund is to invest in rounds with 3 participants. Despite the ALSA Holdings, startups are often financed by Epidarex Capital. The meaningful sponsors for the fund in investment in the same round are Epidarex Capital, AlbionVC. In the next rounds fund is usually obtained by Innovate UK.
The high activity for fund was in 2018. Deals in the range of 5 - 10 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually.
| Fund Name | Location |
| Ackra Invest | Skellefteå, Sweden, Västerbotten County |
| Anhui Huawen Capital Investment Management | Anhui, China, Hefei |
| Beijing Zhongguang Chuangxin Keji Youxianu Gongsi | Beijing, Beijing, China |
| F2 Ventures | England, London, United Kingdom |
| Global Ventures | Dubai, United Arab Emirates |
| Hikari Tsushin Group | Chiyoda, Japan |
| Jiguang | China, Guangdong, Shenzhen |
| Koha Capital | - |
| Korean Impact Collective Funds | Central, Central Region, Singapore |
| LS Group | Seoul, Seoul-t'ukpyolsi, South Korea |
| Maj Invest Equity | Copenhagen, Denmark, Hovedstaden |
| MDL Investments | - |
| Millennium Life Sciences Fund | Anaheim, California, United States |
| Network Solutions | Herndon, United States, Virginia |
| Pilot Grove | - |
| Sixth Sense Ventures | India, Maharashtra, Mumbai |
| TBF Capital Group, LLC | Deerfield, Illinois, United States |
| Valence Ventures | New York, New York, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
IGEM Therapeutics | $6M | 30 Nov 2018 | England |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
IGEM Therapeutics | $6M | 30 Nov 2018 | England |
